Diverse p53 gene aberration in hepatocellular carcinoma detected by dual-color fluorescence in situ hybridization

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 9, 2004, Pages 1066-1073

  Kondo, Masahiko ^a   Marusawa, Hiroyuki ^a   Ueda, Yoshihide ^a   Katsurada, Akira ^a   Kawasome, Chie ^b   Takami, Satoshi ^b   Kinoshita, Moritoshi ^b   Ikai, Iwao ^a   Yamaoka, Yoshio ^a   Chiba, Tsutomu ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b Otsuka Assay Laboratories   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dual color fluorescence in situ hybridization; Loss of heterozygosity; p53; Restriction fragment length polymorphism

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CENTROMERE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOSS; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

EID: 4544225290     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03407.x     Document Type: Article

References (36)

1. Kuroki T, Fujiwara Y, Tsuchiya E et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995; 13: 163-7.
2. Mehta R. The potential for the use of cell proliferation and oncogene expression as intermediate markers during liver carcinogenesis. Cancer Lett. 1995; 93: 85-102.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
4. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. 1971; 68: 820-3.
5. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
6. Buendia MA. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 2000; 10: 185-200.
7. Yumoto Y, Hanafusa T, Hada H et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1995; 10: 179-85.
8. Nishida N, Fukuda Y, Kokuryu H et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res. 1993; 53: 368-72.
9. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S. P53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res. 1994; 54: 231-5.
10. Hsu HC, Peng SY, Lai PL et al. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. Cancer 1994; 73: 42-7.
11. Piao Z, Kim H, Jeon BK, Lee WJ, Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997; 80: 865-72.
12. Kishimoto Y, Shiota G, Kamisaki Y et al. Loss of the tumor suppressor p53 gene at the liver cirrhosis stage in Japanese patients with hepatocellular carcinoma. Oncology 1997; 54: 304-10.
13. Piao Z, Park C, Park JH, Kim H. Allelotype analysis of hepatocellular carcinoma. Int. J. Cancer 1998; 75: 29-33.
14. Shao J, Li X, Liu Z. Loss of heterozygosity on chromosome 17 and 16 in primary hepatocellular carcinomas. Zhonghua Yi Xue Za Zhi 1999; 79: 428-30.
15. Kim H, Lee MJ, Kim MR et al. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver 2000; 20: 173-8.
16. Kobayashi M, Kawashima A, Mai M, Ooi A. Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization. Am. J. Pathol. 1996; 149: 1575-84.
17. Matsumura K, Kallioniemi A, Kallioniemi O et al. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res. 1992; 52: 3474-7.
18. Sauter G, Deng G, Moch H et al. Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am. J. Pathol. 1994; 144: 756-66.
19. Clodi K, Younes A, Goodacre A et al. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br. J. Haematol. 1997; 98: 913-21.
20. Li X, Tsuji T, Wen S, Mimura Y, Sasaki K, Shinozaki F. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer 1997; 79: 2314-19.
21. Amiel A, Arbov L, Manor Y et al. Monoallelic p53 deletion in chronic lymphocytic leukemia detected by interphase cytogenetics. Cancer Genet. Cytogenet. 1997; 97: 97-100.
22. Hartmann A, Rosner U, Schlake G et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Invest. 2000; 80: 709-18.
23. The Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer. Tokyo: Kanehara, 1997.
24. Sambrook JFE, Maniatis T. Molecular Cloning. A Laboratory Manual, Book 2, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 1989.
25. de-la-Calle-Martin O, Fabregat V, Romero M, Soler J, Vives J, Yague J. AccII polymorphism of the p53 gene. Nucleic Acids Res. 1990; 18: 4963.
26. Sameshima Y, Akiyama T, Mori N et al. Point mutation of the p53 gene resulting in splicing inhibition in small cell lung carcinoma. Biochem. Biophys. Res. Commun. 1990; 173: 697-703.
27. Hahn M, Serth J, Fislage R et al. Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin. Chem. 1993; 39: 549-50.
28. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 1992; 5: 89-90.
29. Zimmermann U, Feneux D, Mathey G, Gayral F, Franco D, Bedossa P. Chromosomal aberrations in hepatocellular carcinomas: relationship with pathological features. Hepatology 1997; 26: 1492-8.
30. Nasarek A, Werner M, Nolte M, Klempnauer J, Georgii A. Trisomy 1 and 8 occur frequently in hepatocellular carcinoma but not in liver cell adenoma and focal nodular hyperplasia. A fluorescence in situ hybridization study. Virchows Arch. 1995; 427: 373-8.
31. Hamon-Benais C, Ingster O, Terris B, Couturier-Turpin MH, Bernheim A, Feldmann G. Interphase cytogenetic studies of human hepatocellular carcinomas by fluorescent in situ hybridization. Hepatology 1996; 23: 429-35.
32. Kimura H, Kagawa K, Deguchi T et al. Cytogenetic analyses of hepatocellular carcinoma by in situ hybridization with a chromosome-specific DNA probe. Cancer 1996; 77: 271-7.
33. Kato A, Kubo K, Kurokawa F, Okita K, Oga A, Murakami T. Numerical aberrations of chromosomes 16, 17 and 18 in hepatocellular carcinoma: a FISH and FCM analysis of 20 cases. Dig. Dis. Sci. 1998; 43: 1-7.
34. Huang SF, Hsu HC, Fletcher JA. Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 1999; 111: 21-7.
35. Hartmann A, Zanardo L, Bocker-Edmonston T et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 2002; 62: 6796-802.
36. Kojiro M. Pathology of hepatocellular carcinoma. In: Okuda, K, Tabor, E, eds. Liver Cancer, 1st edn. London: Churchill Livingstone, 1997; 165-87.